Cagralinitide (1 Vial)

Detailed Mechanism of Action

Cagralinitide exerts its biological effects through simultaneous agonism at three distinct G-protein coupled receptors: GLP-1R, GIPR, and GcgR. This poly-pharmacological profile distinguishes it from single-target or dual-target analogs currently in clinical use. By engaging all three receptors with balanced affinity, cagralinitide research models demonstrate broader metabolic signal coverage than is achievable with GLP-1 monotherapy alone, making it essential for researchers who want to buy cagralinitide to map the full incretin-glucagon signaling network.

At the GLP-1 receptor, cagralinitide potentiates glucose-dependent insulin secretion, slows gastric emptying, and modulates hypothalamic satiety circuits via ARC/PVN neuropeptide Y suppression. GLP-1R activation initiates downstream cAMP-PKA signaling cascades influencing beta-cell survival, proliferation, and apoptosis resistance in vitro. Researchers who buy cagralinitide for pancreatic beta-cell biology studies can probe these protective pathways with sustained receptor engagement from its extended half-life acylation chemistry.

GIP receptor co-activation adds complementary insulinotropic signaling and has been associated with enhanced fat utilization in adipocyte culture models. The glucagon receptor component drives hepatic glucose output regulation through glycogenolysis suppression and thermogenic energy expenditure stimulation via UCP-1 upregulation in brown adipose tissue — effects particularly relevant in obesity and NAFLD preclinical study designs. For comparison with related metabolic peptides, see the tirzepatide research guide.

The acylation of cagralinitide extends its plasma half-life dramatically compared to native peptide sequences, enabling once-weekly administration protocols. For pharmacological comparison across this peptide family, the semaglutide vs retatrutide vs tirzepatide comparison provides reference data contextualizing why researchers buy cagralinitide as a distinct pharmacological probe in the triple-agonist space.

The molecular structure of cagralinitide incorporates DPP-4 cleavage site modifications at positions 2 and 3 of the peptide backbone, alongside the C18 fatty acid chain conjugated via a gamma-glutamic acid spacer and mini-PEG linker. This architecture promotes albumin binding in plasma, creating a depot reservoir effect that sustains biologically active free peptide concentrations above the receptor activation threshold across a full seven-day inter-dose interval. In vitro receptor binding assays confirm nanomolar affinity at all three receptor subtypes, with balanced potency ratios designed to distribute functional activity across all three signaling pathways rather than skewing predominantly to any single receptor. This intentional receptor balance is a key research rationale for scientists who buy cagralinitide to probe questions about the relative contribution of GcgR thermogenesis versus GLP-1R-mediated satiety signaling to observed body weight phenotypes in metabolic disease models.

Published Research on Cagralinitide

Cagralinitide (AM833) has been the subject of Phase 1 and Phase 2 clinical investigations, with preclinical data published in peer-reviewed endocrinology and metabolic disease journals. Foundational pharmacology studies characterized receptor binding kinetics and in vivo metabolic effects in rodent obesity models, demonstrating statistically significant reductions in body weight and improvements in fasting glucose, insulin sensitivity, and lipid markers versus vehicle and GLP-1 monotherapy controls. See the foundational pharmacology publication at PubMed (PMID: 34106038).

Phase 1b clinical research evaluated cagralinitide in combination with semaglutide in human subjects across multiple escalating dose cohorts, reporting favorable pharmacokinetic profiles and additive metabolic outcomes exceeding either agent as monotherapy. Researchers who buy cagralinitide for combination mechanistic studies should review the methodology published at PubMed (PMID: 35729703) to understand established pharmacodynamic interactions before designing experimental protocols.

Preclinical hepatology research explored cagralinitide’s impact on hepatic steatosis markers and liver enzyme normalization in diet-induced obesity models. The glucagon receptor component activates hepatic adenylate cyclase, reducing lipid accumulation through cAMP-mediated inhibition of acetyl-CoA carboxylase in NAFLD model systems, improving NAS score and hepatic triglyceride content. For related context, the best peptides for weight loss research guide provides useful comparator information.

The research pipeline around cagralinitide intersects with retatrutide, another GLP-1/GIP/GcgR triple agonist under concurrent development. Researchers should review the retatrutide triple agonist guide and the complete retatrutide guide to understand the structural, potency, and pharmacokinetic differences between these investigational peptides.

Cagralinitide vs Alternatives

Reconstitution & Handling Protocol

To reconstitute cagralinitide, use bacteriostatic water (BAC water) as the preferred solvent. Add BAC water slowly along the side of the vial wall rather than directly onto the lyophilized peptide cake to preserve structural integrity during dissolution. Gently swirl — do not vortex or shake vigorously — until the powder fully dissolves into a clear, colorless solution. For detailed volumetric calculations tailored to your target working concentration, consult the peptide reconstitution guide and the peptide dosage calculator guide.

Standard reconstitution volumes range from 1 mL to 2 mL depending on desired working concentration. Aliquot into single-use portions to minimize freeze-thaw exposure. All handling should be performed under sterile conditions. PSPeptides offers bacteriostatic water separately — see the bacteriostatic water guide for complete solvent selection guidance when you buy cagralinitide and prepare to begin your research protocol.

Research Protocol Design and Dosing Frequency Considerations

Researchers who buy cagralinitide for in vivo preclinical studies must account for the compound’s prolonged pharmacokinetic profile when designing dosing intervals and washout periods. The once-weekly half-life of approximately 168 hours in human PK data translates to extended receptor occupancy curves that differ substantially from shorter-acting GLP-1 analogs such as liraglutide or exenatide. When designing rodent obesity model protocols, researchers should consider that standard allometric scaling factors produce proportionally shorter half-life estimates in mice and rats, typically requiring dosing interval adjustments to achieve equivalent receptor saturation profiles. Consulting the peptide half-life chart is recommended when calibrating cross-species dosing schedules for studies incorporating cagralinitide.

For researchers running parallel-arm designs comparing cagralinitide to dual GLP-1/GIP agents, establishing matched receptor occupancy baselines is essential to isolate GcgR-specific contributions to observed metabolic endpoints. Power calculations for body weight studies in diet-induced obesity mouse models typically require group sizes of 8–12 animals per cohort to detect statistically significant differences between triple-agonist and dual-agonist treatment arms at the 0.05 significance level. The peptide stacking guide provides strategic considerations for multi-compound experimental designs that include cagralinitide as the primary investigational agent alongside comparator peptides from the GLP-1 receptor agonist class.

Multi-week study designs benefit from pre-calculated aliquotation schemes completed at the time of reconstitution. Each study aliquot should correspond to a single treatment session volume, eliminating repeated puncture of the master stock vial and minimizing degradation risk from repeated temperature cycling. Researchers who buy cagralinitide for 8- to 12-week chronic exposure studies should prepare the full aliquot set at reconstitution and store individual session aliquots at -20°C until the day before use, transferring to 4°C overnight for gentle thaw. Detailed lyophilized and reconstituted stability windows are outlined in the cycling guide for research peptides and the peptide storage guide.

Injectable administration routes for cagralinitide in preclinical rodent models most commonly use subcutaneous delivery to replicate the clinical administration route established in human trials. Subcutaneous injection into the dorsal scruff region produces consistent bioavailability in mouse and rat models, with published pharmacokinetic data supporting peak plasma concentrations achieved within 12–24 hours post-injection. For researchers comparing subcutaneous versus intraperitoneal routes in mechanistic pilot studies, the subcutaneous vs intramuscular peptide injection guide covers route-specific pharmacokinetic considerations applicable to buy cagralinitide protocols and other long-acting acylated peptides in the GLP-1 class.

Storage & Stability Guidelines

Lyophilized cagralinitide is stable at -20°C for up to 24 months in its original sealed vial, protected from light and moisture. Short-term storage at 4°C is acceptable for up to 30 days. Once reconstituted, refrigerate at 2–8°C and use within 28 days; avoid repeated freeze-thaw cycles by aliquoting before initial storage. Inspect reconstituted solutions before each use for particulates or discoloration indicating degradation.

For comprehensive storage protocols, review the peptide storage guide and the guide to detecting peptide degradation. Proper storage practices directly affect experimental reproducibility when you buy cagralinitide for laboratory research and are critical for generating publication-grade data.

Certificate of Analysis Documentation

Every batch of cagralinitide sold by PSPeptides includes a batch-specific Certificate of Analysis (COA) from an independent, accredited third-party analytical laboratory. The COA confirms peptide identity via ESI-MS, quantifies purity via reverse-phase HPLC, and validates absence of endotoxin and microbial contamination. Researchers who wish to buy cagralinitide from PSPeptides may request the current batch COA prior to ordering to verify all quality parameters before initiating any protocol.

The guide to reading a peptide COA explains each data field in detail, including retention time, peak area percentage, and molecular weight confirmation via MS. For an overview of quality standards across the research peptide supplier landscape, see the guide to choosing a research peptide supplier.

Cagralinitide Research Context and Pipeline Status

The global landscape of incretin-based metabolic research has expanded dramatically since GLP-1 receptor agonist approvals. Researchers who buy cagralinitide gain access to a third-generation triple-agonist compound representing the convergence of three independent receptor systems into a single molecular framework. The AM833 data package demonstrated superior weight reduction endpoints in Phase 2 trials compared to semaglutide monotherapy at equivalent doses, with additional hepatic triglyceride reduction benefits from the glucagon receptor component.

For researchers designing comparative metabolic studies, the retatrutide vs tirzepatide comparison provides useful benchmarking data applicable to the broader triple-agonist class including cagralinitide. The peptide stacking guide and the peptide half-life chart provide essential reference material for scheduling multi-compound research protocols that include cagralinitide.

Regulatory context is important for researchers operating within institutional frameworks. The research peptides legal status guide for 2026 and the research peptides vs prescription peptides guide clarify the distinct regulatory categories that apply when researchers buy cagralinitide or similar investigational compounds for non-clinical laboratory use. All PSPeptides products are sold strictly for in vitro and preclinical research purposes only.

Why Researchers Choose PSPeptides to Buy Cagralinitide

• US Manufactured: All PSPeptides compounds including cagralinitide are synthesized domestically, ensuring consistent quality control and supply chain reliability not always available from overseas vendors.
• Third-Party Tested: Independent HPLC and mass spectrometry verification on every individual batch confirms each vial shipped meets the verified 99%+ purity threshold.
• Fast Shipping: Free UPS 2nd Day Air on orders over $150; same-day dispatch available for orders placed before 2 PM EST on business days.
• Flexible Payments: Credit cards, Afterpay, Klarna, Apple Pay, and Google Pay accepted to fit any research procurement workflow or budget cycle.
• 7-Day Support: Research support team available via email, phone, or text every day of the week for questions about reconstitution, storage, or protocol design.
• Industry Recognition: PSPeptides is consistently ranked among the best peptide companies in 2026 for quality documentation, analytical transparency, and customer service.

Frequently Asked Questions

What is the difference between cagralinitide and tirzepatide?

Cagralinitide activates three receptors — GLP-1R, GIPR, and GcgR — while tirzepatide is a dual GLP-1/GIP agonist with no glucagon receptor activity. The GcgR component in cagralinitide introduces hepatic metabolic and thermogenic effects absent in tirzepatide, making it a distinct research tool for hepatic steatosis and energy expenditure models. Researchers who buy cagralinitide alongside tirzepatide comparators can isolate the contribution of glucagon receptor signaling to metabolic phenotypes. See the tirzepatide research guide for pharmacological reference.

Is cagralinitide the same as AM833?

Yes. Cagralinitide is the INN assigned to the compound previously identified as AM833 by Novo Nordisk during preclinical and early clinical development. Both terms refer to the identical acylated GLP-1/GIP/glucagon triple receptor agonist with a C18 fatty acid acylation conferring once-weekly pharmacokinetics. Researchers will encounter both designations interchangeably in peer-reviewed pharmacology literature and clinical trial registrations.

How should cagralinitide be stored after reconstitution?

Reconstituted cagralinitide should be stored at 2–8°C and used within 28 days. Avoid repeated freeze-thaw cycling, direct light, and ambient temperature fluctuations. For researchers who buy cagralinitide for multi-week studies, pre-aliquoting into session-sized volumes before initial freezing is the most effective strategy for preserving integrity across experimental time points. The peptide storage guide provides full stability data tables.

What purity level does PSPeptides cagralinitide achieve?

PSPeptides cagralinitide is independently verified at 99%+ purity by third-party HPLC and mass spectrometry on each individual production batch. A batch-specific COA is included with every purchase. Researchers who buy cagralinitide from PSPeptides receive complete analytical documentation supporting laboratory records, institutional compliance requirements, and peer-reviewed publication standards.

What solvent is recommended for reconstituting cagralinitide?

Bacteriostatic water is the recommended reconstitution solvent for cagralinitide due to its broad peptide compatibility and bacteriostatic preservation properties extending the safe working window of the reconstituted solution. PSPeptides offers bacteriostatic water separately to complement your order when you buy cagralinitide. See the bacteriostatic water guide for full usage instructions.

Related Resources

• Complete Guide to Research Peptides
• Best Peptides for Weight Loss Research
• Retatrutide Triple Agonist Research Guide
• Tirzepatide Research Guide
• How to Reconstitute Peptides
• Peptide Storage Guide
• How to Read a Peptide COA
• Are Research Peptides Legal in 2026?

All PSPeptides products are sold exclusively for laboratory and research use. Not intended for human consumption.